Capsid-specific nanobody effects on HIV-1 assembly and infectivity

Alfadhli, Ayna; Romanaggi, Ce Ann; Barklis, Robin Lid; Merutka, Ilaria; Bates, Timothy A.; Tafesse, Fikadu G.; Barklis, Eric

doi:10.1016/j.virol.2021.07.001

Cited by 13 publications

(8 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Structures of Anti-HIV drugs available as per targets. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]…”

Section: Basis For Synthetic Development Of Instismentioning

confidence: 99%

“…Based on the HIV lifecycle, different types of ARV drugs were designed and approved by FDA (Figure 2). [11,12,[13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31] The ART therapy was developed for treatment of HIV patients targeting different targets of viral replication and entry stages.…”

Section: Classification Of Anti-hiv Drugsmentioning

confidence: 99%

“…Based on the HIV lifecycle, different types of ARV drugs were designed and approved by FDA (Figure 2). [11,12,13–31] The ART therapy was developed for treatment of HIV patients targeting different targets of viral replication and entry stages. Hence, the HIV market comprises of combination therapies (NRTIs, NNRTIs, PIs, INSTIs and EIs) which is expanding its limits.…”

Section: Classification Of Anti‐hiv Drugsmentioning

confidence: 99%

“…Wang et al, [53] reported synthesis of intermediate 10 using commercially available starting material 2-aminoisobutyric acid. Loannis et al, [54] reported N-methylation of hexadimethylsilazide to obtain intermediate 28 (Scheme 6) which on deprotection of amine afforded 29 and reaction with oxidazole carboxylic acid (30) gave Raltegravir (2).…”

Section: Synthetic Routes Of Raltegravir (2)mentioning

confidence: 99%

See 3 more Smart Citations

Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)

et al. 2022

View full text Add to dashboard Cite

A clear and precise report on synthetic methods for INSTIs and their intermediates are provided in the present work. HIV Integrase strand transfer inhibitors (INSTIs), a class of antiretroviral agents employed to treat HIV infected patients are placed as the second option of treatment after nucleosides. As INSTIs are employed as first line therapy to newly infected HIV positive individuals, thus synthetic routes must be easily accessible to the medicinal chemists towards lead optimization or process development. The current perspective elaborates synthetic routes of first to next generation INSTIs investigated in two decades of research and their development efforts. Further, drug resistance occurred by mutations against usage of INSTI drugs with respect to their generation also discussed. Later, discussion about synthetic development and investigation of next generation INSTIs against drug resistance HIV infections also covers to fill the gap between first/second generation INSTIs. The current perspective will draw attention of medicinal chemists and multi‐disciplinary researchers in HIV drug discovery.

show abstract

“…Structures of Anti-HIV drugs available as per targets. [13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31]…”

Section: Basis For Synthetic Development Of Instismentioning

confidence: 99%

Section: Classification Of Anti-hiv Drugsmentioning

confidence: 99%

Section: Classification Of Anti‐hiv Drugsmentioning

confidence: 99%

Section: Synthetic Routes Of Raltegravir (2)mentioning

confidence: 99%

See 2 more Smart Citations

Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Moreover VHH have to be modified to ensure that the pI is just below the pH of the cytoplasm [38]. Also intrabodies based on VHH have been applied successfully to combat HIV-1 [40][41][42][43][44] (Table 2). Against representatives of three groups of proteins that have crucial roles in the life cycle of HIV, reverse transcriptase, integrase and nuclear im-and export, VHH have been selected and expressed in cells.…”

Section: Anti Hiv-1 Vhh As Intrabodiesmentioning

confidence: 99%

Known and New Routes to Neutralize HIV-1 with Camelid Single Chain Antibody Fragments

2022

J AIDS HIV Treat

View full text Add to dashboard Cite

Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons

Rizk,

Moustafa,

ElBanna

et al. 2024

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Nanobodies are the smallest known antigen-binding molecules to date. Their small size, good tissue penetration, high stability and solubility, ease of expression, refolding ability, and negligible immunogenicity in the human body have granted them excellence over conventional antibodies. Those exceptional attributes of nanobodies make them promising candidates for various applications in biotechnology, medicine, protein engineering, structural biology, food, and agriculture. This review presents an overview of their structure, development methods, advantages, possible challenges, and applications with special emphasis on infectious diseases-related ones. A showcase of how nanobodies can be harnessed for applications including neutralization of viruses and combating antibiotic-resistant bacteria is detailed. Overall, the impact of nanobodies in vaccine design, rapid diagnostics, and targeted therapies, besides exploring their role in deciphering microbial structures and virulence mechanisms are highlighted. Indeed, nanobodies are reshaping the future of infectious disease prevention and treatment.

show abstract

Capsid-specific nanobody effects on HIV-1 assembly and infectivity

Cited by 13 publications

References 62 publications

Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)

Development of Synthetic Approaches Towards HIV Integrase Strand Transfer Inhibitors (INSTIs)

Known and New Routes to Neutralize HIV-1 with Camelid Single Chain Antibody Fragments

Nanobodies in the fight against infectious diseases: repurposing nature's tiny weapons

Contact Info

Product

Resources

About